Atomoxetine Beyond ADHD: A Fact or Aritfact

Ahmed Naguy
2015 American Journal of Psychiatry and Neuroscience  
Atomoxetine is FDA-approved in Attention-Deficit/Hyperactivity Disorder (ADHD) with demonstrable efficacy and reasonable tolerability. It is classically a selective norepinephrine reuptake inhibitor but data accrues suggestive of an attractive pharmacologic portfolio speaking to the idea of a pluripotent psychotropic agent beyond ADHD. Heaps of cases in the literature abound portraying a multitude of indications with variable level of evidence oscillating from strong to only flimsy. Here, we shed light on these uses and testing extant evidence.
doi:10.11648/j.ajpn.20150305.12 fatcat:mu33sxlig5d73mqwje5w7jt7c4